Cytonics Corporation has initiated enrollment for its Phase 1 clinical trial of CYT-108, a novel variant of alpha-2-macroglobulin (A2M) aimed at addressing cartilage degradation in osteoarthritis (OA). This engineered protein targets proteases

AbbVie has applied to the U.S. Food and Drug Administration and European Medicines Agency for approval of upadacitinib (RINVOQ®; 15 mg, once daily) to treat giant cell arteritis (GCA) in adults.

Tiba Biotech LLC, headquartered in Cambridge, has announced a new collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services

Abeona Therapeutics Inc., a company specializing in cell and gene therapy using adeno-associated virus (AAV) technology, and Beacon Therapeutics, a Syncona-backed firm focusing on ophthalmic gene therapies, have announced a collaboration

HepaRegeniX GmbH, a clinical-stage company focused on developing innovative regenerative therapies for acute and chronic liver diseases, has successfully closed a Series C funding round, raising €15 million

Exscientia plc has recently announced an extended partnership with Amazon Web Services to enhance its drug discovery and automation platform using AWS's artificial intelligence

Rgenta Therapeutics, a biotechnology company specializing in developing oral small molecules that target RNA and RNA regulation for oncology and neurological disorders, has achieved a significant milestone

SciRhom GmbH has successfully concluded a EUR 63 million Series A financing round, co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners

Alteogen Inc. has announced that the Ministry of Food and Drug Safety of Korea has granted approval for its New Drug Application for Tergase® (recombinant hyaluronidase). Developed using Alteogen's proprietary Hybrozyme™ Technology

Mirum Pharmaceuticals, Inc. has announced that the European Commission granted Marketing Authorization for LIVMARLI® oral solution, intended for treating progressive familial intrahepatic